Viatris Inc.

NasdaqGS:VTRS Stok Raporu

Piyasa değeri: US$19.2b

Viatris Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Viatris kazanç ve gelirin sırasıyla yıllık 50.9% ve 1.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 44.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 21.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

50.9%

Kazanç büyüme oranı

44.84%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi14.4%
Gelir büyüme oranı1.8%
Gelecekteki özkaynak getirisi21.87%
Analist kapsamı

Good

Son güncelleme09 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • May 11

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 03

VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential

Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
Anlatı Güncellemesi • Apr 19

VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential

Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.
Anlatı Güncellemesi • Apr 04

VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential

Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
Anlatı Güncellemesi • Mar 21

VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential

Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
Anlatı Güncellemesi • Mar 07

VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations

Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.
Anlatı Güncellemesi • Feb 20

VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk

Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.
Anlatı Güncellemesi • Feb 06

VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential

Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.
Anlatı Güncellemesi • Jan 23

VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential

Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.
Anlatı Güncellemesi • Jan 09

VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns

Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.
Anlatı Güncellemesi • Dec 25

VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance

Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.
Anlatı Güncellemesi • Dec 11

VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance

Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.
Anlatı Güncellemesi • Nov 27

VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead

Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.
Anlatı Güncellemesi • Nov 13

VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead

The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.
Anlatı Güncellemesi • Oct 30

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.
Anlatı Güncellemesi • Oct 15

Aging Populations And Asia Markets Will Unlock Future Value

Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.
Anlatı Güncellemesi • Aug 27

Aging Populations And Asia Markets Will Unlock Future Value

The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
User avatar
Yeni Anlatı • Apr 22

New Product Launches And Expense Savings Will Strengthen Future Operations

New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.
Seeking Alpha • Feb 27

Viatris: One Swallow Doesn't Make A Summer

Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes

Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking Alpha
Seeking Alpha • Nov 08

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Summary Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%. Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act. Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward. With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth. Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end. Read the full article on Seeking Alpha
Seeking Alpha • Oct 22

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Summary Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S ratios suggesting a “screaming buy,” falling revenues and substantial debt challenge Viatris' growth prospects. CEO Scott Smith's “Phase 2” strategy focuses on new product launches and debt reduction, aiming to offset declining sales of older generics and established brands. Viatris' future growth hinges on its innovative pipeline and global infrastructure, with potential blockbuster drugs and a streamlined business model promising profitability and shareholder returns. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:VTRS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202815,2719771,7472,8495
12/31/202715,0394041,7562,8058
12/31/202614,750961,7132,2958
3/31/202614,563-2961,6562,169N/A
12/31/202514,300-3,5151,8512,316N/A
9/30/202514,124-3,6911,5991,983N/A
6/30/202514,116-3,4681,6952,064N/A
3/31/202514,330-3,7901,8392,224N/A
12/31/202414,739-6341,9442,303N/A
9/30/202415,049-8831,8932,389N/A
6/30/202415,239-6461,8842,397N/A
3/31/202415,361-562,0002,543N/A
12/31/202315,427552,3252,900N/A
9/30/202315,4661,8322,0232,474N/A
6/30/202315,6021,8542,0452,508N/A
3/31/202315,8001,9042,3322,785N/A
12/31/202216,2632,0792,5102,999N/A
9/30/202216,7288042,8353,333N/A
6/30/202217,1877613,0353,550N/A
3/31/202217,6481682,7793,307N/A
12/31/202117,886-1,2692,5083,017N/A
9/30/202117,168-1,9211,7842,530N/A
6/30/202115,604-2,0471,2961,969N/A
3/31/202113,757-1,7281,1661,790N/A
12/31/202011,946-6705511,232N/A
9/30/202011,5142661,5391,882N/A
6/30/202011,5042711,5021,845N/A
3/31/202011,624631,6872,135N/A
12/31/201911,50117N/A1,804N/A
9/30/201911,38748N/A1,753N/A
6/30/201911,28834N/A1,919N/A
3/31/201911,245240N/A1,680N/A
12/31/201811,434353N/A2,342N/A
9/30/201811,594546N/A2,201N/A
6/30/201811,719457N/A2,096N/A
3/31/201811,873717N/A2,234N/A
12/31/201711,908696N/A2,065N/A
9/30/201711,937869N/A1,919N/A
6/30/201712,007661N/A2,571N/A
3/31/201711,605533N/A2,420N/A
12/31/201611,077480N/A2,047N/A
9/30/201610,300257N/A2,350N/A
6/30/20169,938806N/A2,124N/A
3/31/20169,749805N/A1,822N/A
12/31/20159,429848N/A2,009N/A
9/30/20159,021842N/A1,483N/A
6/30/20158,410913N/A949N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VTRS önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: VTRS önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: VTRS önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: VTRS şirketinin gelirinin (yıllık 1.8% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VTRS şirketinin gelirinin (yıllık 1.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VTRS 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 21.9 %)

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/17 14:34
Gün Sonu Hisse Fiyatı2026/05/15 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Viatris Inc. 31 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jasper HellwegArgus Research Company
Glen SantangeloBarclays
Aaron GalBernstein